Alpha-1 Antitrypsin Deficiency
According to the National Organization for Rare Disorders (NORD), alpha-1 antitrypsin deficiency (AATD) is a rare hereditary (autosomal recessive) metabolic disorder characterized by low levels of a protein called alpha-1 antitrypsin (A1AT), found in the blood. It can cause chronic obstructive pulmonary obstructive disease (COPD); COPD may often have emphysema symptoms. Besides, few adults with
AATD develop liver damage (cirrhosis) due to the formation of scar tissue in the liver.
&nbsp;
Alpha-1 Antitrypsin Deficiency Epidemiology Segmentation in the 7MM
&nbsp;
<ul>
<li class="ql-align-justify">Total Prevalent Cases</li>
<li class="ql-align-justify">Symptom-specific Cases</li>
<li class="ql-align-justify">Total Diagnosed Cases</li>
<li class="ql-align-justify">Genotype-specific Cases</li>
<li class="ql-align-justify">Comorbidity-specific Cases</li>
</ul>
&nbsp;
<a href="https://www.delveinsight.com/report-store/alpha-1-antitrypsin-deficiency-epidemiology-forecast" target="_blank" rel="noopener noreferrer">Alpha-1 Antitrypsin Deficiency Epidemiological Insights Observed in the 7MM</a> (2021)
The total number of incident cases of Alpha-1 Antitrypsin Deficiency observed in the 7MM was observed to be 190K in the year 2021.
&nbsp;
<a href="https://www.delveinsight.com/report-store/alpha-1-antitrypsin-deficiency-a1atd-market" target="_blank" rel="noopener noreferrer">Alpha-1 Antitrypsin Deficiency Market Insight</a>
The market size of Alpha-1 Antitrypsin Deficiency in the 7MM was found to be approximately USD 1,200 million in 2021.
&nbsp;
Alpha-1 Antitrypsin Deficiency Market Strengths
Due to the rising incidence and prevalence of AATD, companies focus on developing effective treatments for patients with better safety compared to the current standard of care.&nbsp;
&nbsp;
Alpha-1 Antitrypsin Deficiency Market Opportunities
Drugs for treating liver disease in AATD have the advantage of grabbing an untapped market in this indication. The first to enter the market is expected to take a greater market segment.
&nbsp;
<a href="https://www.delveinsight.com/report-store/alpha-1-antitrypsin-deficiency-aatd-pipeline-insight" target="_blank" rel="noopener noreferrer">Alpha-1 Antitrypsin Deficiency Emerging Drugs and Key Companies</a>
&nbsp;
<ul>
<li class="ql-align-justify">ARO-AAT (Fazirsiran): Arrow Head Pharmaceuticals</li>
<li class="ql-align-justify">Alvelestat (MPH-966): Mereo Biopharma</li>
<li class="ql-align-justify">Inhaled AAT: Kamada Ltd</li>
</ul>
&nbsp;

Alpha-1 Antitrypsin Deficiency Market

Alpha-1 Antitrypsin Deficiency Market Infographics

Alpha-1 Antitrypsin Deficiency Symptoms, Treatment, epidemiology, companies, drugs, infographic is a short guide to understand the problem and market landscape